Cellebrite DI (CLBT) Current Deferred Revenue (2019 - 2025)

Cellebrite DI's Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $277.6 million for Q4 2025.

• In Q4 2025, Current Deferred Revenue rose 5.86% year-over-year to $277.6 million; the TTM figure through Dec 2025 stood at $277.6 million (up 5.86% YoY), while the FY2025 annual figure was $277.6 million, up 5.86% from the prior year.
• Current Deferred Revenue was $277.6 million for Q4 2025 at Cellebrite DI, up from $239.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $277.6 million in Q4 2025 to a low of $115.0 million in Q3 2021.
• Historically, Current Deferred Revenue has averaged $187.6 million across 5 years, with a median of $185.0 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue surged 34.06% in 2023, then rose 5.86% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $159.4 million in 2021, then gained by 22.25% to $194.9 million in 2022, then advanced by 24.6% to $242.8 million in 2023, then increased by 7.99% to $262.2 million in 2024, then climbed by 5.86% to $277.6 million in 2025.
• The last three Current Deferred Revenue figures came in at $277.6 million (Q4 2025), $239.7 million (Q3 2025), and $227.2 million (Q2 2025), per Business Quant data.